Sign Out
Type 2 Diabetes Mellitus: As monotherapy in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
In combination with other antidiabetic agents [e.g., metformin and/or a sulfonylurea, a thiazolidinedione, a dipeptidyl peptidase-4 (DPP-4) inhibitor and/or insulin or a glucagon-like peptide 1 (GLP-1) receptor agonist (prolonged-release exenatide)] in patients with type 2 diabetes mellitus as an adjunct to diet and exercise who have not achieved adequate glycemic control.
In patients with type 2 diabetes mellitus and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors to reduce the risk of hospitalization for heart failure.
Limitations of Use: Dapagliflozin is not indicated for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Heart Failure: For the treatment of heart failure in patients with reduced ejection fraction.
Continue with Google